Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Beats Estimates By $0.03 EPS

Abbott Laboratories (NYSE:ABT) issued its earnings results on Thursday. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03, FiscalAI reports. The business had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 EPS. Abbott Laboratories updated its Q3 2026 guidance to 1.380-1.46 EPS and its FY 2026 guidance to 5.450-5.60 EPS.

Abbott Laboratories Trading Up 0.3%

Shares of Abbott Laboratories stock opened at $89.27 on Thursday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market cap of $155.49 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 1.53 and a beta of 0.61. The firm has a fifty day moving average price of $89.33 and a 200 day moving average price of $102.36.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares in the last quarter. United Bank boosted its stake in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC grew its holdings in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analysts expect Abbott’s upcoming Q2 results to show healthy revenue and earnings growth, supported by strong performance in Diagnostics, Devices and Emerging Pharmaceutical/EPD segments. Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition
• Positive Sentiment: Coverage around Abbott’s cancer diagnostics strategy highlights longer-term growth potential, with management continuing to invest in improving tests and expanding the business after the Exact Sciences acquisition. Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
• Positive Sentiment: Analysts are still recommending investors retain Abbott shares for now, citing emerging-market pharmaceutical growth and continued innovation in nutrition as potential supports for the stock. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Neutral Sentiment: Market commentary says Abbott is one of the names investors are watching as earnings season begins, but the article is mainly a watchlist note rather than fresh company-specific news. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Neutral Sentiment: Another brief market note also flags Abbott ahead of earnings, reinforcing that the stock is being traded around the upcoming results. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Negative Sentiment: Risks remain from macro pressure and foreign exchange swings, which could weigh on results even if core business trends stay healthy. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Negative Sentiment: Nutrition remains a drag in the near term, and some coverage notes that this segment could limit upside if other divisions do not fully offset it. Abbott’s Q2 Earnings on Deck: How Should You Play the Stock Now?

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ABT shares. BTIG Research reissued a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. Bank of America dropped their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Jefferies Financial Group cut their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. Finally, Mizuho cut their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $117.61.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.